NeoGenomics, Inc.
NeoGenomics, Inc. (NEO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NEO · as of Jun 8, 2026
Key Statistics
Explore NeoGenomics, Inc. Data
neo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 29 · Buy rate: 79.3%
The NEO analyst consensus is Buy, based on ratings from 29 Wall Street analysts over the past 3 months. The average 12-month price target is $19.00, representing +73.52% upside from the current price of $10.95.
Competitors & Peers
neo competitorsNEO
ACRS
ARCT
HUMA
MDXH
QTRXStock Performance
Full HistoryAbout NeoGenomics, Inc.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company o…
what is neogenomics, inc. · neo stock overview · neogenomics, inc. company profile · who is neogenomics, inc. ceo · neo NASDAQ · neogenomics, inc. headquarters · neogenomics, inc. business segments
About Stock Overview & Key Data
NeoGenomics, Inc. (NEO) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Mar 16, 2004. As of the latest trading session, NEO stock price is $10.95, with a market capitalization of $285.2M. The stock has returned +44.84% over the past 12 months and -6.89% year-to-date.
According to 29 Wall Street analysts, the consensus rating for NeoGenomics, Inc. stock is Buy, with an average 12-month price target of $19.00. In fiscal year 2025, NeoGenomics, Inc. reported revenue of $727.3M and net income of -$108.0M. For detailed data — including NeoGenomics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, NeoGenomics, Inc. (NEO) stock price is $10.95. The stock is traded on NASDAQ under the ticker symbol NEO. The 52-week range is $4.72 – $13.74.